NCT07266129 Virtual Biopsy of Prostate Cancer Using PSMA PET and AI
| NCT ID | NCT07266129 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital of North Norway |
| Condition | Prostate Cancer (Diagnosis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 220 participants |
| Start Date | 2024-06-03 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 220 participants in total. It began in 2024-06-03 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prostate cancer is the most common type of cancer in Norwegian men, but many tumors are slow-growing and do not require treatment. Today, MRI is good at detecting suspicious lesions, yet it cannot reliably distinguish aggressive tumors from low-grade ones. As a result, many men undergo repeated invasive biopsies. New PET tracers targeting PSMA improve tumor localization and may correlate with cancer aggressiveness, offering potential for better assessment. This project aims to develop a method to predict Gleason Score non-invasively by applying machine learning to PET and MRI data. The work involves early static and dynamic PSMA PET imaging, tracer kinetic modelling, deep learning, and validation of PET-based measurements of PSMA internalization using ex-vivo cellular methods. If successful, the project could reduce the number of biopsies, improve diagnostic accuracy, offer full 3D assessment of the prostate, shorten clinical workflows, and help identify patients who would benefit most from PSMA-based radioligand therapy.
Eligibility Criteria
Inclusion Criteria: * For patients who have undergone biopsies prior to PET: * Patients referred to clinical PET examination * For patients who have not had biopsies prior to PET: * Patients referred to urologist for suspected prostate cancer based on clinical symptoms or elevated PSA-levels Exclusion Criteria: * Prostatektomy * Body weight under 100 kg * MRI incompatible implants or other incompatibilities
Frequently Asked Questions
Who can join the NCT07266129 clinical trial?
This trial is open to male participants only, studying Prostate Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07266129 currently recruiting?
Yes, NCT07266129 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital of North Norway to inquire about joining.
Where is the NCT07266129 trial being conducted?
This trial is being conducted at Tromsø, Norway.
Who is sponsoring the NCT07266129 clinical trial?
NCT07266129 is sponsored by University Hospital of North Norway. The trial plans to enroll 220 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.